Artax Biopharma
  • Resources
  • Partners
  • News
  • Contact us
  • Our Approach
  • Our Patients
  • About Artax
  • Our Pipeline and Progress

Press Releases

  • Feature May 9, 2025

    Artax Biopharma presents Phase 2a results for oral Nck modulator AX-158 in late-breaking session at the Society for Investigative Dermatology 2025 Annual Meeting

    First small molecule to modulate the fundamental mechanism ofT cell activation underlying autoimmune pathology Statistically…
    • Scientific Publication
    • Press Releases
    • Media
    • Press Releases
    May 9, 2025

    Artax Biopharma presents Phase 2a results for oral Nck modulator AX-158 in late-breaking session at the Society for Investigative Dermatology 2025 Annual Meeting

    First small molecule to modulate the fundamental mechanism ofT cell activation underlying autoimmune pathology Statistically…
    • Press Releases
    Apr 23, 2025

    Artax Biopharma to present Phase 2a data on Nck modulatorAX-158, establishing novel mechanism of action in autoimmune disease at the 2025 SID Annual Meeting

    Late breaker abstract presentation to showcase clinical validation of first-in-class oral small molecule AX-158 in…
    • Press Releases
    Mar 7, 2025

    Artax Biopharma presents new preclinical data on Nck modulators at 2025 AAD Annual Meeting

    Cambridge, MA, March 7, 2025 – Artax Biopharma, Inc., a clinical-stage biotechnology company focused on transforming the…
    • Press Releases
    Mar 3, 2025

    Artax Biopharma to present on first-in-class Nck modulator at the 2025 AAD Annual Meeting

    Poster presentation on evaluation of Nck modulator in atopic dermatitis models Cambridge, MA, March 3,…
    • Press Releases
    Jan 22, 2025

    Artax Biopharma achieves clinical validation of first-in-class, oral,  Nck modulator AX-158 for autoimmune disease in phase 2a study

    Cambridge, MA, January 22, 2025 – Artax Biopharma, Inc., a clinical-stage biotechnology company focused on transforming the…
    • Press Releases
    Oct 1, 2024

    Artax Biopharma to present first-in-class Nck modulator mechanism of action and Phase 1 data at the ACR Annual Meeting

    Cambridge, MA, October 1, 2024 – Artax Biopharma, Inc., a clinical-stage biotechnology company focused on…
    • Press Releases
    Aug 13, 2024

    Artax Biopharma completes patient recruitment in Phase 2a trial with first-in-class Nck modulator AX-158

    AX-158 has broad potential to treat many autoimmune diseases without causing immunosuppression. Psoriasis biomarker panel and PASI scores…
    • Press Releases
    Aug 6, 2024

    Artax Biopharma Raises $8 Million Ahead of Phase 2a Data Expected in Q4-2024

    Strong support from existing shareholders which includes Lilly, Advent Life Sciences, Columbus Ventures, Sound Bioventures and Belinda Termeer Cambridge,…
    • Press Releases
    Feb 13, 2024

    Artax Announces First Patient Dosed in Phase 2a Psoriasis Trial Evaluating AX-158

    Artax Announces First Patient Dosed in Phase 2a Psoriasis Trial Evaluating AX-158
1 2 3
Next

1 in 10 individuals is affected by autoimmune disease –
join our mission to treat them

Interested in learning more?

Ask us a question – the Artax team can help you

Get in touch
Clinical trials participation

Help us evaluate Nck modulation in clinical trials

About clinical trials
Partner with Artax

Explore Nck modulators for autoimmune conditions

About partnering with Artax

© Artax Biopharma. All Rights Reserved.

Terms of Use | Privacy Policy

Artax Biopharma
Manage Consent
To provide the best experiences, we use technologies like cookies to store and/or access device information. Consenting to these technologies will allow us to process data such as browsing behavior or unique IDs on this site. Not consenting or withdrawing consent, may adversely affect certain features and functions.
Functional Always active
The technical storage or access is strictly necessary for the legitimate purpose of enabling the use of a specific service explicitly requested by the subscriber or user, or for the sole purpose of carrying out the transmission of a communication over an electronic communications network.
Preferences
The technical storage or access is necessary for the legitimate purpose of storing preferences that are not requested by the subscriber or user.
Statistics
The technical storage or access that is used exclusively for statistical purposes. The technical storage or access that is used exclusively for anonymous statistical purposes. Without a subpoena, voluntary compliance on the part of your Internet Service Provider, or additional records from a third party, information stored or retrieved for this purpose alone cannot usually be used to identify you.
Marketing
The technical storage or access is required to create user profiles to send advertising, or to track the user on a website or across several websites for similar marketing purposes.
Manage options Manage services Manage {vendor_count} vendors Read more about these purposes
View preferences
{title} {title} {title}